329 related articles for article (PubMed ID: 17919086)
1. A role for JAK2 mutations in myeloproliferative diseases.
Morgan KJ; Gilliland DG
Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
[TBL] [Abstract][Full Text] [Related]
2. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
3. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
5. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
6. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
7. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
8. JAK-2 mutations and their relevance to myeloproliferative disease.
Levine RL; Gilliland DG
Curr Opin Hematol; 2007 Jan; 14(1):43-7. PubMed ID: 17133099
[TBL] [Abstract][Full Text] [Related]
9. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
10. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
11. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
[TBL] [Abstract][Full Text] [Related]
12. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
14. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
15. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
16. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
17. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
18. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
19. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
20. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
